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Bortezomib (BTZ) is an eff ective antineoplastic drug that acts by inhibiting the 
ubiquitin-proteasome cellular pathways. In clinical practice, its chronic administra-
tion triggers a signifi cant neurotoxicity, which has been associated with impairment 
of Aβ, Aδ, and C type primary aff erent fi bers, though the mechanism underlying its 
harmful eff ects remains still to be fully clarifi ed. In order to mimic the clinical use of 
the drug, we have recently designed an experimental model based on the use of 0,20 
mg/kg drug concentration for 8 weeks followed by a follow-up period of 4 weeks. 
We have previously shown that, in these conditions, a hallmark of neurotoxicity is 
represented by a small fi ber neuropathy, whereas dorsal root ganglia (DRG) neurons 
did not show any morphological alterations. In order to provide data regarding the 
mechanism underlying BTZ harmful eff ects, here we characterize the spinal primary 
sensory neurons on the basis of their expression of the transient receptor potential 
vanilloid type-1 (TRPV1) and sensory neuropeptides calcitonin gene-related peptide 
(CGRP) and substance P (SP). In fact, TRPV1 is expressed by sensory neurons where 
it functions as a molecular integrator for nociception. Its activation causes depolari-
sation leading to burning pain and release of CGRP and SP which, in turn, activate 
their eff ector cell receptors and enhance the sensitization of nociceptors. With this 
aim, lumbar DRG and spinal cord of BTZ-treated model rats were processed for avi-
dine-biotin-peroxidase complex or ﬂ uorescence immunohistochemistry. In the DRG, 
the immunolabelling for TRPV1 revealed a subpopulation of predominantly small- to 
medium-sized neurons which appeared more extensive in BTZ-treated rats. Centrally, 
TRPV1-LI labelled fi ber tracts and terminal-like elements distributed in laminae I and 
II of the dorsal horn where they appeared widely codistributed with both CGRP-LI 
and SP-LI. With the exception of a slight more intense TRPV1 staining in lamina I of 
the dorsal horn of BTZ-treated vs control rats, no clear-cut diff erences in the distribu-
tion and amount of immunoreactivity for the three markers could be observed.
Keywords: Bortezomib, TRPV1, neuropeptides, DRG, spinal cord, rat
